Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
AstraZeneca
Mallinckrodt
Medtronic
Boehringer Ingelheim

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,151,103

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,151,103 protect, and when does it expire?

Patent 7,151,103 protects ADDYI and is included in one NDA.

This patent has forty-two patent family members in twenty-nine countries.

Summary for Patent: 7,151,103
Title:Method of treating female hypoactive sexual desire disorder with flibanserin
Abstract: The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
Inventor(s): Borsini; Franco (Bad Waldsee, DE), Evans; Kenneth Robert (Toronto, CA)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:10/272,603
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,151,103

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes   Start Trial   Start Trial USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,151,103

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01125020Oct 20, 2001

International Family Members for US Patent 7,151,103

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 037109   Start Trial
Argentina 077480   Start Trial
Austria 327757   Start Trial
Australia 2002333894   Start Trial
Brazil 0213358   Start Trial
Canada 2458067   Start Trial
China 101347431   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Merck
AstraZeneca
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.